Puma Biotechnology (NASDAQ:PBYI) Director Sells $158,840.00 in Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Jay Moyes sold 22,000 shares of the stock in a transaction on Friday, June 12th. The stock was sold at an average price of $7.22, for a total value of $158,840.00. Following the completion of the transaction, the director owned 58,322 shares of the company’s stock, valued at $421,084.84. The trade was a 27.39% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Puma Biotechnology Stock Performance

NASDAQ:PBYI traded down $0.26 during trading hours on Monday, hitting $7.07. The company’s stock had a trading volume of 177,368 shares, compared to its average volume of 189,537. The business’s 50-day moving average is $7.23 and its two-hundred day moving average is $6.57. The company has a market capitalization of $359.86 million, a PE ratio of 14.73 and a beta of 1.21. Puma Biotechnology, Inc. has a 52-week low of $3.03 and a 52-week high of $7.90.

Puma Biotechnology (NASDAQ:PBYI) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.09. The firm had revenue of $44.81 million during the quarter, compared to analysts’ expectations of $42.00 million. Puma Biotechnology had a return on equity of 20.30% and a net margin of 10.69%. As a group, analysts predict that Puma Biotechnology, Inc. will post 0.28 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on PBYI shares. Weiss Ratings cut Puma Biotechnology from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Wall Street Zen cut Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 16th. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat.com, the stock has an average rating of “Hold”.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Dimensional Fund Advisors LP increased its position in shares of Puma Biotechnology by 7.2% in the first quarter. Dimensional Fund Advisors LP now owns 1,436,106 shares of the biopharmaceutical company’s stock valued at $9,175,000 after buying an additional 96,503 shares in the last quarter. O Shaughnessy Asset Management LLC increased its position in Puma Biotechnology by 35.3% during the 4th quarter. O Shaughnessy Asset Management LLC now owns 1,120,329 shares of the biopharmaceutical company’s stock worth $6,666,000 after purchasing an additional 292,108 shares in the last quarter. Geode Capital Management LLC increased its position in Puma Biotechnology by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 994,345 shares of the biopharmaceutical company’s stock worth $5,917,000 after purchasing an additional 10,823 shares in the last quarter. Russell Investments Group Ltd. increased its position in Puma Biotechnology by 4,823,365.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 964,693 shares of the biopharmaceutical company’s stock worth $5,123,000 after purchasing an additional 964,673 shares in the last quarter. Finally, State Street Corp increased its position in Puma Biotechnology by 17.2% during the 4th quarter. State Street Corp now owns 877,077 shares of the biopharmaceutical company’s stock worth $5,219,000 after purchasing an additional 128,419 shares in the last quarter. Hedge funds and other institutional investors own 61.29% of the company’s stock.

About Puma Biotechnology

Puma Biotechnology, Inc is a late?stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small?molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early?stage HER2-positive breast cancer.